A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.

Inclusion criteria

• Male or female, 19-75 years of age
• diagnosed with type 2 diabetes mellitus
• Patients who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies;

• Metformin
• Sulphonylurea
• Thiazolidinedione
• Metformin and sulphonylurea
• Metformin and thiazolidinedione

Exclusion criteria

• Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following medications:

• Alpha glucosidase inhibitor or meglitinide within 30 days of screening;
• Insulin within 2 weeks prior to screening or insulin for longer than 1 week within 3 months of screening;
• DPP-4 inhibitors within 30 days of screening;
• Regular use (> 14 days) of drugs that directly affect gastrointestinal motility within 3 months of screening;
• Regular use (> 14 days) of systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption within 3 months of screening;
• GLP-1 receptor agonist except exenatide within 3 months of screening;
• diagnosed with type 1 diabetes mellitus or diabetic ketoacidosis;
• type 2 diabetes by beta-cell dysfunction requiring insulin treatment
• Has ever used exenatide
• Pregnant or breast feeding patients
• Hepatic disease (defined by aspartate or alanine transaminase >3.0 times the upper limit of normal
• End-stage renal disease or severe renal impairment (creatinine clearance < 30 ml/min)